| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2023 | 27.81% | Needham | $55 → $46 | Maintains | Buy |
| 10/10/2023 | 11.14% | Goldman Sachs | $45 → $40 | Maintains | Sell |
| 10/03/2023 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 09/01/2023 | 52.82% | Needham | → $55 | Reiterates | Buy → Buy |
| 08/30/2023 | 44.48% | Citigroup | → $52 | Initiates Coverage On | → Neutral |
| 08/07/2023 | 27.81% | Credit Suisse | $47 → $46 | Maintains | Neutral |
| 08/04/2023 | 27.81% | Morgan Stanley | $45 → $46 | Maintains | Underweight |
| 08/03/2023 | 52.82% | Needham | $58 → $55 | Maintains | Buy |
| 07/13/2023 | 30.59% | Credit Suisse | $46 → $47 | Maintains | Neutral |
| 06/20/2023 | 30.59% | Stephens & Co. | → $47 | Reiterates | Equal-Weight → Equal-Weight |
| 05/09/2023 | 27.81% | Credit Suisse | $44 → $46 | Maintains | Neutral |
| 05/05/2023 | 25.03% | Morgan Stanley | $40 → $45 | Maintains | Underweight |
| 05/05/2023 | 61.16% | Needham | → $58 | Reiterates | → Buy |
| 02/23/2023 | 22.26% | Credit Suisse | $41 → $44 | Upgrades | Underperform → Neutral |
| 02/21/2023 | 25.03% | Stephens & Co. | → $45 | Reiterates | → Equal-Weight |
| 02/17/2023 | 61.16% | Needham | $54 → $58 | Maintains | Buy |
| 02/01/2023 | — | Northcoast Research | Downgrades | Buy → Neutral | |
| 01/17/2023 | 11.14% | Morgan Stanley | $41 → $40 | Downgrades | Equal-Weight → Underweight |
| 12/13/2022 | 13.92% | Credit Suisse | → $41 | Initiates Coverage On | → Underperform |
| 11/22/2022 | 38.93% | Cowen & Co. | $55 → $50 | Downgrades | Outperform → Market Perform |
| 11/07/2022 | 80.61% | Raymond James | $75 → $65 | Maintains | Strong Buy |
| 11/04/2022 | 50.04% | Needham | $52 → $54 | Maintains | Buy |
| 10/12/2022 | 13.92% | Morgan Stanley | $45 → $41 | Maintains | Equal-Weight |
| 09/20/2022 | 44.48% | Needham | $50 → $52 | Maintains | Buy |
| 08/12/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 08/04/2022 | 25.03% | Morgan Stanley | $52 → $45 | Maintains | Equal-Weight |
| 08/03/2022 | 52.82% | Cowen & Co. | $75 → $55 | Maintains | Outperform |
| 08/03/2022 | 108.39% | Raymond James | $80 → $75 | Maintains | Strong Buy |
| 08/03/2022 | 80.61% | Bernstein | → $65 | Upgrades | Market Perform → Outperform |
| 08/03/2022 | 25.03% | Stephens & Co. | $80 → $45 | Downgrades | Overweight → Equal-Weight |
| 08/03/2022 | 38.93% | Needham | $60 → $50 | Maintains | Buy |
| 08/01/2022 | 66.71% | Needham | $80 → $60 | Maintains | Buy |
| 06/23/2022 | 13.92% | Goldman Sachs | $59 → $41 | Maintains | Sell |
| 06/09/2022 | 122.28% | Raymond James | $90 → $80 | Maintains | Strong Buy |
| 05/31/2022 | 44.48% | Morgan Stanley | $68 → $52 | Maintains | Equal-Weight |
| 05/26/2022 | 38.93% | UBS | $80 → $50 | Maintains | Neutral |
| 05/09/2022 | 150.07% | Raymond James | $110 → $90 | Maintains | Strong Buy |
| 05/06/2022 | 88.94% | Morgan Stanley | $80 → $68 | Maintains | Equal-Weight |
| 05/06/2022 | 122.28% | Needham | $95 → $80 | Maintains | Buy |
| 04/07/2022 | 122.28% | Morgan Stanley | $75 → $80 | Maintains | Equal-Weight |
| 03/07/2022 | 86.16% | Goldman Sachs | $77 → $67 | Maintains | Sell |
| 02/18/2022 | 108.39% | Morgan Stanley | $83 → $75 | Maintains | Equal-Weight |
| 02/18/2022 | 88.94% | JP Morgan | $80 → $68 | Upgrades | Underweight → Neutral |
| 01/25/2022 | 108.39% | Daiwa Capital | $81 → $75 | Upgrades | Neutral → Outperform |
| 01/14/2022 | 130.62% | Morgan Stanley | $85 → $83 | Maintains | Equal-Weight |
| 11/12/2021 | 177.85% | Cowen & Co. | $110 → $100 | Maintains | Outperform |
| 11/12/2021 | 136.18% | Morgan Stanley | $78 → $85 | Upgrades | Underweight → Equal-Weight |
| 11/08/2021 | — | Northcoast Research | Upgrades | Neutral → Buy | |
| 11/08/2021 | 163.96% | Needham | → $95 | Upgrades | Hold → Buy |
| 11/08/2021 | 205.64% | Raymond James | $120 → $110 | Maintains | Strong Buy |
| 10/07/2021 | 105.61% | Morgan Stanley | $79 → $74 | Maintains | Underweight |
| 05/19/2021 | 233.43% | Raymond James | $100 → $120 | Upgrades | Outperform → Strong Buy |
| 05/07/2021 | 100.06% | Morgan Stanley | $68 → $72 | Maintains | Underweight |
| 02/12/2021 | 191.75% | Cowen & Co. | $85 → $105 | Maintains | Outperform |
| 02/12/2021 | 88.94% | Morgan Stanley | $62 → $68 | Maintains | Underweight |
| 02/12/2021 | 177.85% | Raymond James | $75 → $100 | Maintains | Outperform |
| 01/20/2021 | 72.27% | Morgan Stanley | $57 → $62 | Maintains | Underweight |
| 01/14/2021 | 205.64% | HSBC | $77 → $110 | Upgrades | Hold → Buy |
| 10/29/2020 | 58.38% | Morgan Stanley | $55 → $57 | Maintains | Underweight |
| 10/16/2020 | 136.18% | Stephens & Co. | → $85 | Initiates Coverage On | → Overweight |
| 09/04/2020 | — | Daiwa Capital | Downgrades | Outperform → Neutral | |
| 07/31/2020 | 52.82% | Morgan Stanley | $39 → $55 | Maintains | Underweight |
| 06/02/2020 | 25.03% | Baird | $44 → $45 | Downgrades | Neutral → Underperform |
| 05/26/2020 | 52.82% | HSBC | → $55 | Initiates Coverage On | → Hold |
| 05/08/2020 | 55.6% | UBS | $43 → $56 | Maintains | Neutral |
| 04/28/2020 | 22.26% | Baird | $44 → $44 | Maintains | Neutral |
| 04/28/2020 | 8.36% | Morgan Stanley | $39 → $39 | Maintains | Underweight |
| 04/28/2020 | 66.71% | Raymond James | $48 → $60 | Maintains | Outperform |
| 04/17/2020 | 11.14% | JP Morgan | $36 → $40 | Maintains | Underweight |
| 03/23/2020 | 0.03% | Morgan Stanley | $42 → $36 | Downgrades | Equal-Weight → Underweight |
| 03/17/2020 | 16.7% | Morgan Stanley | $49 → $42 | Maintains | Equal-Weight |
| 02/19/2020 | 36.15% | Morgan Stanley | $47 → $49 | Maintains | Equal-Weight |
| 12/12/2019 | 44.48% | UBS | → $52 | Initiates Coverage On | → Neutral |
| 09/23/2019 | 25.03% | DA Davidson | $40 → $45 | Maintains | Neutral |
| 09/23/2019 | 30.59% | Baird | $42 → $47 | Maintains | Neutral |
| 07/16/2019 | 0.03% | Goldman Sachs | $45 → $36 | Downgrades | Neutral → Sell |
| 07/10/2019 | 19.48% | Morgan Stanley | $47 → $43 | Maintains | Equal-Weight |
| 04/30/2019 | — | Needham | Downgrades | Buy → Hold | |
| 04/30/2019 | — | Bernstein | Downgrades | Outperform → Market Perform | |
| 04/17/2019 | — | Gordon Haskett | Initiates Coverage On | → Hold |
What is the target price for Cognex (CGNX)?
The latest price target for Cognex (NASDAQ: CGNX) was reported by Needham on November 1, 2023. The analyst firm set a price target for $46.00 expecting CGNX to rise to within 12 months (a possible 27.81% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cognex (CGNX)?
The latest analyst rating for Cognex (NASDAQ: CGNX) was provided by Needham, and Cognex maintained their buy rating.
When is the next analyst rating going to be posted or updated for Cognex (CGNX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cognex, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cognex was filed on November 1, 2023 so you should expect the next rating to be made available sometime around November 1, 2024.
Is the Analyst Rating Cognex (CGNX) correct?
While ratings are subjective and will change, the latest Cognex (CGNX) rating was a maintained with a price target of $55.00 to $46.00. The current price Cognex (CGNX) is trading at is $35.99, which is out of the analyst's predicted range.